

# Albin Jeanne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8584283/publications.pdf>

Version: 2024-02-01

9  
papers

324  
citations

1307594

7  
h-index

1588992

8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

537  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Ovarian Carcinoma with TSP-1:CD47 Antagonist TAX2 Activates Anti-Tumor Immunity. <i>Cancers</i> , 2021, 13, 5019.	3.7	14
2	Assessment of Ovarian Tumor Growth in Wild-Type and Lumican-Deficient Mice: Insights Using Infrared Spectral Imaging, Histopathology, and Immunohistochemistry. <i>Cancers</i> , 2021, 13, 5950.	3.7	0
3	Towards the Therapeutic Use of TSP-1 (Thrombospondin-1)/CD47 Targeting TAX2 Peptide as an Antithrombotic Agent. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 41, e1-e17.	2.4	7
4	Deciphering the complex role of thrombospondin-1 in glioblastoma development. <i>Nature Communications</i> , 2019, 10, 1146.	12.8	143
5	Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide. <i>Scientific Reports</i> , 2017, 7, 7700.	3.3	31
6	Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma. <i>Pediatric Research</i> , 2017, 81, 480-488.	2.3	9
7	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 637-649.	3.3	16
8	Original insights on thrombospondin-1-related antireceptor strategies in cancer. <i>Frontiers in Pharmacology</i> , 2015, 6, 252.	3.5	86
9	Identification of TAX2 peptide as a new unpredicted anti-cancer agent. <i>Oncotarget</i> , 2015, 6, 17981-18000.	1.8	18